George W Sledge MD

🧠 #SABCS25: #AI models outperformed standard tools for predicting distant recurrence in patients with early-stage #BreastCancer, enabling more individualized risk assessment and treatment decision guidance. 👨‍⚕️ @jsparano | Eleftherios Mamounas, MD 🔗 ascopost.com/news/december-…

Possible mechanisms of resistance to T-DXd in breast cancer patients using real-world data and multiomic profiling ⬆️ABCC1 and ⬇️ERBB2 showed ⬇️OS, in line with previous works on T-DXd. Presented at #SABCS24, now published on @Nature_NPJ by @GeorgeSledge51 et al. (link below)

@thenasheffect @ConquerCancerFd @ASCO @BurrisSkip @jrgralow @ASCOPres Congrats to Rafeh. Well done.

Honored to be selected for an oral presentation at the Annual @ConquerCancerFd retreat! Without doubt the work @ConquerCancerFd does is phenomenal! Trainees apply for Merit Awards/ YIA/CDA and other opportunities! @ASCO @BurrisSkip @jrgralow @ASCOPres

A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors jamanetwork.com/journals/jamao… Trastuzumab deruxtecan-nxki (T-DXd) received tumor-agnostic FDA approval in April 2024 for adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors lacking other treatment options, based on responses seen across three DESTINY trials. This prompted widespread HER2 IHC testing across tumor types, leading to the first large-scale report on real-world HER2 IHC 3+ prevalence using standardized interpretation criteria. Among over 65,000 tested patients, HER2 IHC 3+ rates varied widely by cancer type, with #BladderCancer showing the highest prevalence (13.9%), while others—like gliomas, sarcomas, #ProstateCancer, and kidney cancers—had minimal or no expression. These findings suggest universal HER2 testing may not be necessary for all solid tumors, and a more targeted approach—initiating HER2 IHC only after identifying ERBB2 amplification or overexpression via comprehensive genomic profiling—could reduce unnecessary testing while optimizing workflow and cost-efficiency. Dave Bryant Rebecca Feldman Farah Abdulla Daniel Magee Jennifer R. Ribeiro Matthew Oberley Milan Radovich David Spetzler @carisls @GeorgeSledge51

@TNBCFoundation @HayleyDinerman What a champion for women with TNBC. And what a great supporter for the researchers trying to end this scourge. Hayley, we owe you a great debt for your tireless work.

💜For 18 years, Hayley Dinerman has led the TNBC Foundation with heart and vision—turning a grassroots effort into a national force for hope, research, and community. As @hayleydinerman transitions to our Board, we celebrate her incredible legacy. #ThankYouHayley #TNBCF

@carisls Our paper is the first broad view of tissue agnostic indications based on a large, solid dataset. We need to rethink what “tissue agnostic “ means, and how we approach tissue agnostic approvals.

Caris has published a 295,000+ patient study revealing variable efficacy among cancers for patients treated with tissue-agnostic drugs and uncovering the potential for expanding approvals to other drugs in the same class. Learn more: ow.ly/Ii5x50VlbqJ

Triple Negative Breast Cancer is a complex and aggressive form of breast cancer. Ahead of Triple Negative Breast Cancer Awareness Month, what is one thing you wish others were aware about living with TNBC? Share your experiences in the comments 👇 #TNBCFoundation #TNBC

@PamelaKunzMD @YaleMed @YaleCancer @ericwiner @ROYHERBST Congratulations and well deserved.

With gratitude and excitement, I am happy to share that I’ve been promoted to Professor of Medicine (Oncology). It's been a long journey since my white coat ceremony. @YaleMed @YaleCancer @ericwiner @royherbst 🧵1/6

Caris Chief Scientific Officer Milan Radovich, PhD, shares insights on how Caris Assure sets a new benchmark in #liquidbiopsy profiling. Join us in transforming patient care through innovative solutions: ow.ly/4LGf50TVt28

This week, we highlighted two recent collaborative publications by researchers, including @EHeath4100, @KelseyAPoorman, @JoanneXiu, @SamuelKareffMD, @marshalj23, @saikatbib, @Marindoc, @jpshen_md and others published in @BrJCancer and @CRC_AACR. bit.ly/3zlVK8H.

@VanAllenLab Hello, 1960 calling and it’s looking for its technology.

Never gonna give you up

@PTarantinoMD Underpowered trial is my guess

MONARCH 3 final OS results. Statistically negative (p=0.06), but hard to argue that 13.1 months delta in OS does not denote a clinical benefit. annalsofoncology.org/article/S0923-…

In addition to our paper ja.ma/47EB7zR, I’d also like to point you to the editorial jamanetwork.com/journals/jama/… and @kristac's piece on it med.stanford.edu/news/all-news/….

@SKabrajiMD @DrHBurstein @ac_palmer E1193 for targeted therapy

@DrHBurstein If we add 3 active drugs would expect their PFS to be longer than 2 by additivity alone as per @ac_palmer nature.com/articles/s4301… Without OS data and clear tox do we help our pts by giving these together instead of sequentially?

The cohort in INAVO120 was quite endocrine resistant. But PFS of 15m for triplet would be longer than 1st line F + palbo (7m) followed by F + capi (7.3m) even w/o the more limited PFS with F + capi in CDK46i-treated cohort (5.5M). If true would suggest triplet should be standard.

Also for TROPION 01, obviously need OS. For field as a whole we could use structured crossover trials from ADC1–>ADC2. And we need a better understanding of resistance: resistance based on target vs payload.

TROPION Breast01 updated from October ESMO shows 2.4 mo improvement in PFS vs ineffective late line CT with improved QOL vs CT. Question: should we require, going forward, comparisons vs other ADCs rather than vs essentially inactive CT?

Monarch 3 frontline OS results for Abema continue to show numerically impressive improvements but a significant p value remains frustratingly elusive. This is confusing given positive second line and adjuvant results.

With both neoadjuvant Nivo and Pembro in ER pos BC pCR rates increase strongly as PD-L1 increases. Two questions: should we use PD-L1 as a predictive biomarker, and should we use either of these drugs in the absence of solid EFS improvements?

@DrSGraff Just so long as it wasn’t me.

@GeorgeSledge51 Trying to keep the comment generic, @GeorgeSledge51. I can take photos and name names…but that’s not quite my style. 😉 The rowdy fan analogy seemed a good enough fit.

💡Yelp, Day 1️⃣ of #ASCO23 and I have an idea: If I go to an NFL game for example, and someone around me is rude or disruptive, I can text the “rowdy fan” help number and an usher comes and helps me. No idea what is going on here…but we need a “usher to the rescue” help line.